BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

17 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

08 12 2024 13:45:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

07 12 2024 11:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

06 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

04 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

12 11 2024 16:01:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

05 11 2024 09:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

05 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

29 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

06 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces Transition of Chief Financial Officer

15 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

26 6 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

14 6 2024 03:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

30 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

14 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

08 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

07 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

26 3 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

28 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

27 2 2024 06:30:00 提供 Nasdaq GlobeNewswire